ITeos Therapeutics Inc (ITOS)
10.78
+0.22
(+2.08%)
USD |
NASDAQ |
Apr 22, 16:00
10.78
0.00 (0.00%)
After-Hours: 20:00
ITeos Therapeutics Cash from Financing (TTM): 1.113M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 1.113M |
September 30, 2023 | 2.18M |
June 30, 2023 | 2.169M |
March 31, 2023 | 2.229M |
December 31, 2022 | 1.984M |
September 30, 2022 | 2.966M |
June 30, 2022 | 3.408M |
March 31, 2022 | 3.325M |
December 31, 2021 | 3.659M |
Date | Value |
---|---|
September 30, 2021 | 2.136M |
June 30, 2021 | 214.57M |
March 31, 2021 | 213.27M |
December 31, 2020 | 340.34M |
September 30, 2020 | 339.51M |
June 30, 2020 | 126.70M |
March 31, 2020 | 150.28M |
December 31, 2019 | 22.54M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.113M
Minimum
Dec 2023
340.34M
Maximum
Dec 2020
84.26M
Average
3.408M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Gilead Sciences Inc | -5.125B |
Merck & Co Inc | -4.81B |
Arcus Biosciences Inc | 33.00M |
IGM Biosciences Inc | 115.07M |
Forian Inc | -4.602M |